Clinical trial
Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone…
NCT03874013 · OPKO Health, Inc., Industry · Completed
Key facts
| NCT number | NCT03874013 |
|---|---|
| Title | Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency |
| Official title | A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency |
| Lead sponsor | OPKO Health, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Growth Hormone Deficiency |
| Intervention type | Drug |
| Interventions | MOD-4023, Genotropin |
| Enrollment | 44 |
| Start date | Dec 7, 2017 |
| Primary completion | Mar 6, 2020 |
| Completion | Mar 6, 2020 |
| First posted | Mar 14, 2019 |
| Last update posted | Aug 12, 2021 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: